Intra-Cellular Therapies (ITCI) Competitors $84.51 -1.13 (-1.32%) (As of 10:31 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ITCI vs. VIE, RARX, AIMT, ZYME, KURA, BNTX, TEVA, BGNE, VTRS, and MRNAShould you be buying Intra-Cellular Therapies stock or one of its competitors? The main competitors of Intra-Cellular Therapies include Viela Bio (VIE), Ra Pharmaceuticals (RARX), Aimmune Therapeutics (AIMT), Zymeworks (ZYME), Kura Oncology (KURA), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Viatris (VTRS), and Moderna (MRNA). These companies are all part of the "medical" sector. Intra-Cellular Therapies vs. Viela Bio Ra Pharmaceuticals Aimmune Therapeutics Zymeworks Kura Oncology BioNTech Teva Pharmaceutical Industries BeiGene Viatris Moderna Intra-Cellular Therapies (NASDAQ:ITCI) and Viela Bio (NASDAQ:VIE) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, community ranking, profitability, valuation, institutional ownership and risk. Does the media favor ITCI or VIE? In the previous week, Intra-Cellular Therapies had 8 more articles in the media than Viela Bio. MarketBeat recorded 8 mentions for Intra-Cellular Therapies and 0 mentions for Viela Bio. Intra-Cellular Therapies' average media sentiment score of 1.05 beat Viela Bio's score of 0.00 indicating that Intra-Cellular Therapies is being referred to more favorably in the media. Company Overall Sentiment Intra-Cellular Therapies Positive Viela Bio Neutral Which has more volatility & risk, ITCI or VIE? Intra-Cellular Therapies has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Viela Bio has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Do institutionals and insiders hold more shares of ITCI or VIE? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 47.0% of Viela Bio shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by insiders. Comparatively, 31.5% of Viela Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts recommend ITCI or VIE? Intra-Cellular Therapies currently has a consensus price target of $97.23, suggesting a potential upside of 15.05%. Given Intra-Cellular Therapies' stronger consensus rating and higher probable upside, research analysts plainly believe Intra-Cellular Therapies is more favorable than Viela Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85Viela Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in ITCI or VIE? Intra-Cellular Therapies received 519 more outperform votes than Viela Bio when rated by MarketBeat users. Likewise, 67.84% of users gave Intra-Cellular Therapies an outperform vote while only 40.00% of users gave Viela Bio an outperform vote. CompanyUnderperformOutperformIntra-Cellular TherapiesOutperform Votes52167.84% Underperform Votes24732.16% Viela BioOutperform Votes240.00% Underperform Votes360.00% Which has stronger valuation & earnings, ITCI or VIE? Viela Bio has lower revenue, but higher earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Viela Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$464.37M19.29-$139.67M-$0.87-97.14Viela Bio$50M58.26-$86.43M-$7.02-7.55 Is ITCI or VIE more profitable? Viela Bio has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat Viela Bio's return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Viela Bio N/A -33.97%-31.49% SummaryIntra-Cellular Therapies beats Viela Bio on 13 of the 18 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Intra-Cellular Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITCI vs. The Competition Export to ExcelMetricIntra-Cellular TherapiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.96B$6.48B$5.07B$8.80BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-97.144.9789.5613.60Price / Sales19.29371.451,224.8087.40Price / CashN/A52.5939.4536.27Price / Book7.8310.306.976.33Net Income-$139.67M$153.61M$119.04M$225.93M7 Day Performance-3.56%-1.73%-1.78%-0.96%1 Month Performance9.88%-7.26%-3.59%1.06%1 Year Performance44.39%31.10%31.64%26.59% Intra-Cellular Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITCIIntra-Cellular Therapies4.4737 of 5 stars$84.51-1.3%$97.23+15.1%+46.2%$8.96B$464.37M-97.14560Positive NewsVIEViela BioN/A$53.01flatN/AN/A$2.91B$50M-7.55166RARXRa PharmaceuticalsN/A$47.99flatN/A+0.0%$2.27B$3M-20.7772AIMTAimmune TherapeuticsN/A$34.49flatN/AN/A$2.26BN/A-8.69228ZYMEZymeworks2.4008 of 5 stars$14.07-3.3%$19.00+35.0%+74.0%$969.14M$76.01M0.00290KURAKura Oncology4.0972 of 5 stars$10.03-37.0%$29.43+193.4%+66.6%$779.93MN/A-4.73142Analyst ForecastNews CoverageHigh Trading VolumeBNTXBioNTech3.4725 of 5 stars$102.75+0.6%$138.79+35.1%+3.3%$24.63B$4.13B0.006,133Analyst ForecastAnalyst RevisionTEVATeva Pharmaceutical Industries2.7027 of 5 stars$17.16+0.8%$19.67+14.6%+80.0%$19.44B$15.85B-20.0337,851BGNEBeiGene3.1891 of 5 stars$195.50+0.6%$247.07+26.4%+3.4%$19.04B$2.46B-23.5810,600Analyst DowngradeGap UpVTRSViatris1.3514 of 5 stars$13.16+0.2%$13.33+1.3%+38.6%$15.71B$15.43B0.0038,000MRNAModerna4.6292 of 5 stars$36.62-0.9%$84.00+129.4%-53.2%$14.09B$6.85B-6.355,600Analyst UpgradeAnalyst Revision Related Companies and Tools Related Companies VIE Alternatives RARX Alternatives AIMT Alternatives ZYME Alternatives KURA Alternatives BNTX Alternatives TEVA Alternatives BGNE Alternatives VTRS Alternatives MRNA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ITCI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intra-Cellular Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ITCI Stock Alerts